Elutia Inc's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 89/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 3.50.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Elutia Inc's Score
Industry at a Glance
Industry Ranking
89 / 158
Overall Ranking
222 / 4582
Industry
Pharmaceuticals
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
2
analysts
Buy
Current Rating
3.500
Target Price
+416.22%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Elutia Inc Highlights
StrengthsRisks
Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Women’s Health and Cardiovascular markets. In Women’s Health, it offers SimpliDerm, a novel biological matrix that leverages the inherent science of natural healing processes. SimpliDerm's design uses human-based hydrated acellular dermal matrix (ADM), which mitigates inflammation and enhances tissue incorporation. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population. It is focused on advancing NXT-41x, a biomatrix that directly addresses the root causes of reconstruction infections following mastectomy. NXT-41x combines biologics and extended antibiotic release to provide protection while supporting tissue regeneration.
Growing
The company is in a growing phase, with the latest annual income totaling USD 24.38M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 24.38M.
Overvalued
The company’s latest PE is -0.94, at a high 3-year percentile range.
Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Women’s Health and Cardiovascular markets. In Women’s Health, it offers SimpliDerm, a novel biological matrix that leverages the inherent science of natural healing processes. SimpliDerm's design uses human-based hydrated acellular dermal matrix (ADM), which mitigates inflammation and enhances tissue incorporation. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population. It is focused on advancing NXT-41x, a biomatrix that directly addresses the root causes of reconstruction infections following mastectomy. NXT-41x combines biologics and extended antibiotic release to provide protection while supporting tissue regeneration.
Ticker SymbolELUT
CompanyElutia Inc
CEOMills (C. Randal)
Websitehttps://elutia.com/
FAQs
What is the current price of Elutia Inc (ELUT)?
The current price of Elutia Inc (ELUT) is 0.586.
What is the symbol of Elutia Inc?
The ticker symbol of Elutia Inc is ELUT.
What is the 52-week high of Elutia Inc?
The 52-week high of Elutia Inc is 4.840.
What is the 52-week low of Elutia Inc?
The 52-week low of Elutia Inc is 0.500.
What is the market capitalization of Elutia Inc?
The market capitalization of Elutia Inc is 24.95M.
What is the net income of Elutia Inc?
The net income of Elutia Inc is -53.95M.
Is Elutia Inc (ELUT) currently rated as Buy, Hold, or Sell?
According to analysts, Elutia Inc (ELUT) has an overall rating of Buy, with a price target of 3.500.
What is the Earnings Per Share (EPS TTM) of Elutia Inc (ELUT)?
The Earnings Per Share (EPS TTM) of Elutia Inc (ELUT) is -0.626.